实用肿瘤学杂志 ›› 2013, Vol. 27 ›› Issue (2): 105-110.doi: 10.3969/j.issn.1002-3070.2013.02.003

• 论著 • 上一篇    下一篇

血管紧张素Ⅱ对乳腺癌细胞基质金属蛋白酶调节机制研究

刘炜,蔡莉,刘美燕,杨春雨,赵艳滨   

  1. 哈尔滨医科大学附属肿瘤医院内四科(哈尔滨 150040)
  • 收稿日期:2012-04-20 出版日期:2013-04-28 发布日期:2013-04-26
  • 通讯作者: 赵艳滨,E-mail:zhaoyanbin1978@sina.com
  • 作者简介:刘炜,女,(1982-),硕士,主治医师,从事乳腺癌的诊治研究
  • 基金资助:
    哈尔滨医科大学附属肿瘤医院内基金(2009-33);黑龙江省卫生厅项目(2010-113);黑龙江省教育厅项目(12521246)

The mechanism of the Angiotensin Ⅱ on the regulation of matrix metalloproteinases

LIU Wei,CAI LI,LIU Meiyan,YANG Chunyu,ZHAO Yanbin   

  1. Department of Medical Oncology,The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081,China
  • Received:2012-04-20 Online:2013-04-28 Published:2013-04-26

摘要: 目的探讨血管紧张素Ⅱ(Angiotensin Ⅱ)对乳腺癌MCF-7细胞基质金属蛋白酶表达和活性的影响。方法 体外培养乳腺癌MCF-7细胞,经血管紧张素II及血管紧张素Ⅱ 1型受体阻断剂(氯沙坦)处理后,用MTT法检测细胞增殖能力的变化,RT-PCR法检测MMP-2、MMP-9、TIMP-1和TIMP-2 mRNA的表达情况,明胶酶谱法检测MMP-2和MMP-9酶活性的变化。结果 血管紧张素Ⅱ可以促进乳腺癌细胞的生长,并且呈现剂量和时间依赖性;血管紧张素Ⅱ可上调MMP-2和MMP-9 mRNA的表达,抑制TIMP-1和TIMP-2 mRNA的表达,同时增强MMP-2和MMP-9酶的活性,其中100nM的血管紧张素Ⅱ作用最显著(P<0.05)。用氯沙坦预先处理细胞可以显著抑制血管紧张素Ⅱ对基质金属蛋白酶表达和活性的调节作用。结论 血管紧张素Ⅱ通过与血管紧张素Ⅱ 1型受体结合来调节乳腺癌细胞基质金属蛋白酶的表达,其受体阻断剂(氯沙坦)可以显著抑制血管紧张素Ⅱ的作用。因此血管紧张素Ⅱ/血管紧张素Ⅱ1型受体有可能成为乳腺癌治疗的靶点。

Abstract: Objective To study the effect of Angiotensin Ⅱ on cell proliferation and the activity of matrix metalloproteinase in breast cancer cells.Methods MCF-7 cells were cultured in vitro and stimulated with Angiotensin Ⅱ and/or Losartan.The viability of cells was tested by MTT assay.We used RT-PCR to detect the mRNA level of MMP-2,MMP-9,TIMP-1 and TIMP-2.The activity of MMP-2 and MMP-9 were measured by gelatin zymography.Results Angiotensin Ⅱ stimulated the growth of breast cancer cells in a dose-and time-dependent manner.Moreover,the expressions of MMP-2 and MMP-9 mRNA were significantly up-regulated by Angiotensin Ⅱ.The expressions of TIMP-1 and TIMP-2 mRNA were significantly down-regulated by Angiotensin Ⅱ.In addition,Angiotensin Ⅱ significantly enhanced the activity of MMP-2 and MMP-9.Angiotensin Ⅱ had a maximal response with 100nM(P<0.05).Losartan significantly decreased the effect of Angiotensin Ⅱ on matrix metalloproteinase.Conclusion In summary,our study can support the concept that Angiotensin Ⅱ/ Angiotensin Ⅱ type 1 receptor(AT1R)signaling can regulate the expression of matrix metalloproteinase.Losartan can significantly decrease the effect of Angiotensin Ⅱ on matrix metalloproteinase.Therefore,targeting Angiotensin Ⅱ/ Angiotensin Ⅱ type 1 receptor(AT1R)signaling could be a novel therapeutic for breast cancer.

中图分类号: